261 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 261 dated studies on Insulin. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
This review provides crucial insights for refining diabetes management protocols in intensive care settings, highlighting the need for highly individualized approaches. Understanding the specific conditions that dicta…
This review provides crucial, evidence-based guidance that can significantly improve patient safety and surgical outcomes for individuals with diabetes. By offering clear protocols for adjusting diabetes medications i…
This research highlights Kisspeptin's potential as a therapeutic agent for mitigating the adverse effects of maternal hypothyroidism on pregnancy outcomes. The restoration of placental mTOR signaling and glucose homeo…
This synthesis of evidence underscores the critical role of growth hormone (GH) in driving breast cancer progression, metastasis, and angiogenesis, moving beyond the traditional focus on steroid hormones. Understandin…
This comprehensive review highlights the critical role of IGF-1 in MASLD pathogenesis, suggesting it's not just a correlative factor but potentially a key player. The most significant implication is that IGF-1 levels …
The establishment of accurate normative ranges for IGF-1, IGFBP-3, and ALS is profoundly important for pediatric endocrinology. These reference values provide clinicians with the necessary tools to differentiate betwe…
This global registry represents a crucial step in understanding the long-term safety and effectiveness of Increlex® for SPIGFD. By collecting data from a large, diverse patient population over many years, it can ident…
If successful, this research could provide a non-pharmacological strategy to mitigate breast cancer risk in individuals with BRCA mutations. Understanding the impact of diet on biomarkers like IGF-I could empower muta…
This commentary highlights a crucial aspect of drug development: accurately identifying the mechanism of action. If adipotide truly reduces fat by inducing apoptosis of blood vessels in white adipose tissue, it repres…
This research suggests that epigenetic clocks could become a powerful tool for early-life risk stratification, identifying teenagers on a trajectory toward premature cardiovascular disease long before traditional sign…
This research positions `GPER` agonism as a viable and distinct therapeutic strategy for **obesity** and **type 2 diabetes**, particularly in contexts like postmenopause where traditional hormone replacement has risks…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This Phase 3 trial is crucial for optimizing Type 2 Diabetes management by evaluating a potentially simpler, yet effective, treatment option. If IDegLira demonstrates comparable efficacy and a favorable safety profile…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
The key implication of this research is the potential for IDegLira to offer a significantly safer and more effective therapeutic option for Type 2 Diabetes patients transitioning from hospital to home. By reducing the…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
These findings suggest that **IGF-1 LR3 could be a viable strategy to safely increase both heart muscle and its supporting blood supply before birth**. For potential therapeutic applications aimed at improving congeni…
This research provides a potential mechanistic explanation for the reduced β-cell function seen in overgrown newborns from pregnancies complicated by conditions like diabetes. The finding that elevated IGF-1 can direc…
This research is critical for understanding the molecular mechanisms behind skin aging and its response to environmental stressors like UVB. If Insulin-Like Growth Factor 1 proves effective in modulating gene expressi…
The exploration of ARA 290, a non-hematopoietic erythropoietin analogue, holds significant promise as it targets a novel mechanism for glucose regulation, potentially offering a new therapeutic avenue beyond existing …
While this specific study did not yield results, the initial intent highlights the potential scientific interest in Kisspeptin-10 as a modulator of insulin secretion. If future research successfully demonstrates a rol…
Understanding the interplay between reproductive hormones like kisspeptin and metabolic processes could open new avenues for treating metabolic diseases. If kisspeptin were found to positively influence insulin secret…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
This summary highlights the continued global scientific focus on obesity as a multifaceted disease with profound implications for public health. The emphasis on novel therapeutic approaches presented at the WCIRDC sug…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…
Preserving lean muscle mass during rapid weight loss is critical for maintaining metabolic rate, improving insulin sensitivity, and preventing weight regain, especially in individuals with Type 2 Diabetes Mellitus. Th…
This case report highlights the potential efficacy and safety of GLP-1 receptor agonists (GLP1RAs), specifically semaglutide, in managing the challenging glycemic control associated with mitochondrial diabetes in pedi…
This review highlights a paradigm shift in how dysglycemia might be managed in acute care settings. If GLP-1 RAs prove safe and effective in this population, they could offer a novel therapeutic strategy to improve ou…
Free, no account — handy when you're working with Insulin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account